All In MedTech

Device Trial Radar · NCT07607496

MacuTherm Performance Study in Patients With iAMD

Individualized Navigated Photothermal Therapy in Patients With Intermediate AMD: A Randomized, Double-Blinded, Controlled Clinical Trial to Evaluate the Performance of theTherapy Proposed by Macula Explorer Using Navilas Laser System

Last checked: Nov 19, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 240 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

240

Planned (sponsor's estimate)

Start

May 29, 2026

Primary completion

Dec 2027

Study completion Dec 2028

Sponsor

Lead sponsor
OD-OS MacuTherm GmbHNot on our public-company list
Sponsor type
Industry
First posted
May 26, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, outcomes assessor)
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 60 years, up to 90 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this study is to demonstrate that photothermal therapy with the individually dosed treatment plan proposed by Macula Explorer delivered safely by Navilas® Laser System effectively improves the life of photoreceptors and reduces the progression of intermediate Age-related Macular Degeneration (iAMD) and preserves photoreceptors shown by Ellipsoid Zone Integrity (EZI). Participants will be randomized to either Treatment or Control Group. There will be 12 visits, monthly for the first 3 months, then quarterly until the end of the study after 2 years.

Conditions

  • Intermediate AMD

Interventions

  • photothermal therapyDevice

    Patients receive individualized photothermal therapy in the study eye

  • Sham treatmentDevice

    Patients receive sham treatment in the study eye

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Primary endpoint is defined by preservation of Ellipsoid Zone Integrity (EZI).Time frame: 12 months

Locations

10 sites in 2 countries. Site status is shown where the registry gives one.

  • Gemeinschaftspraxis GbR Dr. Giers, Dr. Faßbender & Partner

    Detmold, Germany · Recruiting

  • Department of Ophthalmology at Hannover Medical School

    Hanover, Germany · Recruiting

  • Department of Ophthalmology, University Medical Center Schleswig-Holstein

    Lübeck, Germany · Recruiting

7 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.